A randomized, open-label phase 2 study of 2 regimens, gemcitabine plus enzastaurin and single-agent gemcitabine, in patients with locally advanced or metastatic pancreatic cancer

Trial Profile

A randomized, open-label phase 2 study of 2 regimens, gemcitabine plus enzastaurin and single-agent gemcitabine, in patients with locally advanced or metastatic pancreatic cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2009

At a glance

  • Drugs Enzastaurin; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Aug 2007 Status changed from recruiting to in progress.
    • 31 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top